TITLE

OREXO'S ASTRAL GETS TWO MORE EU MARKET APPROVALS

PUB. DATE
April 2009
SOURCE
Worldwide Biotech;Apr2009, Vol. 21 Issue 4, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on Marketing Authorizations received by Orexo from the regulatory authorities of France and Spain for AbstralTM, a drug used for the treatment of cancer pain. ProStrakan, Orexo's exclusive licensing partner for AbstralTM in Europe and North America is expected to launch the drug in the two countries in the second half of 2009. According to Torbjom Bjerke, president and chief executive officer (CEO) of Orexo, the royalties from the product would enable them to become a sustainable, profitable pharmaceutical company.
ACCESSION #
37135398

 

Related Articles

  • OREXO/PROSTRAKAN EXTEND LICENSING PACT FOR RAPINYL (ABSTRAL).  // Worldwide Biotech;Sep2008, Vol. 20 Issue 9, p2 

    The article reports on the extension of the European licensing agreement between Swedish pharmaceutical company Orexo AB and Scottish specialty pharmaceutical company ProStrakan Group PLC. The agreement involves the drug Rapinyl for breakthrough cancer pain and Orexo covering North America....

  • $210M Deal Gives Endo Rights to Testosterone Gel Fortesta. Hollingsworth, Catherine // BioWorld International;9/2/2009, Vol. 14 Issue 35, p1 

    The article reports that marketing rights to testosterone gel Fortesta in the U.S. has been acquired by Endo Pharmaceuticals Inc. from Prostrakan Group PLC of Great Britain. The deal for the hormone replacement therapy is valued at up to 210 million U.S. dollars. It provides an overview of...

  • OREXO/KYOWA HAKKO KIRIN DISTRIBUTE KW-2246 FOR CANCER PAIN.  // Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p7 

    The article reports on the joint distribution agreement signed between Kyowa Hakko Kirin Co. Ltd. and pharmaceutical firm Hisamitsu Pharmaceutical Co. Inc. Kyowa will primarily handle the approval process for the product in Japan. Under the terms of the agreement, the two companies will jointly...

  • R&D Update.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p18 

    The article offers news briefs related to research and development in the pharmaceutical industry. Pfizer Inc. has reported positive results from Phase IV Embeda studies. Durect Corp. has announced results from the Phase III study for POSIDUR known as Bupivacaine Effectiveness and Safety (BESST)...

  • ProStrakan to launch Abstrai in France.  // PharmaWatch: CNS;Aug2009, Vol. 8 Issue 8, p15 

    The article reports on the plan of ProStrakan Group PLC to introduce Abstral, a cancer pain drug, in France in July 2009. The drug obtained positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency in June 2008. Moreover, the drug was also...

  • Orexo: Abstral(r) Launched and Now Available in the US.  // Biomedical Market Newsletter;5/21/2011, p407 

    The article reports on the launch of Abstral, fast-acting sublingual tablet for cancer pain, by the partner of Orexo AB, ProStrakan Group PLC in the U.S. It mentions that in 2010 the market value for fast-acting fentanyl products have reached 530 million dollars. It notes that Abstral has been...

  • Pain Licensing Update.  // PharmaWatch: CNS;Dec2005, Vol. 4 Issue 12, p17 

    The article presents news briefs related to the pharmaceutical industry. SkyePharma PLC and the Japanese firm Maruho entered into a marketing partnership to develop and commercialize DepoBupivacaine, which is an injectable local anesthetic. King Pharmaceuticals Inc. entered into an agreement...

  • Orexo acquires US commercial rights of Abstral and ProStrakan acquires the corresponding rights in the EU and rest of the world.  // Biomedical Market Newsletter;6/7/2012, Vol. 21, p1 

    The article informs that ProStrakan Group PLC and Orexo AB have acquired all rights to Abstral in the Europe and the U.S. respectively. It mentions that Abstral is an opoid which is used for the treatment of breakthrough pain in cancer patients. It further informs that ProStrakan will acquire...

  • $210M Deal Gives Endo Rights to Testosterone Gel Fortesta. Hollingsworth, Catherine // BioWorld Today;8/27/2009, Vol. 20 Issue 165, p1 

    The article reports that Prostrakan Group plc awarded the marketing rights for its hormone replacement therapy, Fortesta, in the U.S. to Endo Pharmaceuticals Inc. The said rights agreement, which is said to be worth up to 210 million U.S. dollars, entails the exclusive supply of the testosterone...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics